

Peer Review

# Review of: "Mirtazapine as an Appetite Stimulant in Patients With Non–Small Cell Lung Cancer"

Masashi Namba<sup>1</sup>

1. Independent researcher

I think this is a valuable paper. There are several important points that require modification:

1. While the critique mentions that the definition of sarcopenia is unclear, it is actually well-defined in the Appendix. However, since sarcopenia is evaluated using CT scans, it may not be rigorously evaluated. In that sense, the authors' point seems reasonable.
2. The variation in the number of patients evaluated across different figures is somewhat unavoidable, as patient data can sometimes be missing. The study likely submitted supplementary materials, appendices, and raw data, which should ensure the validity of the data.
3. The low incidence of mirtazapine side effects is addressed in the Discussion. It's important to note that patient backgrounds can vary significantly between clinical trials, which may be a crucial factor.
4. The JAMA Oncology study suggests that mirtazapine may be effective in non-small cell lung cancer patients with relatively well-maintained general and nutritional status. The study's limitations are also clearly stated in the LIMITATIONS section.

Based on the above points, please revise the main text.

## Declarations

**Potential competing interests:** No potential competing interests to declare.